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We performed a genome-scale shRNA screen for modula-
tors of B-cell leukemia progression in vivo. Results from
this work revealed dramatic distinctions between the
relative effects of shRNAs on the growth of tumor cells
in culture versus in their native microenvironment. Spe-
cifically, we identified many ‘‘context-specific’’ regulators
of leukemia development. These included the gene encod-
ing the zinc finger protein Phf6. While inactivating muta-
tions in PHF6 are commonly observed in human myeloid
and T-cell malignancies, we found that Phf6 suppression in
B-cell malignancies impairs tumor progression. Thus, Phf6
is a ‘‘lineage-specific’’ cancer gene that plays opposing roles
in developmentally distinct hematopoietic malignancies.
Supplemental material is available for this article.
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28, 2015.
Retroviral insertional mutagenesis screens (Lund et al.
2002; Mikkers et al. 2002; Suzuki et al. 2002) and trans-
poson-based screens (Collier et al. 2005; Dupuy et al. 2005)
have been used as powerful tools for cancer gene discovery
in hematopoietic and solid tumors. These screens have
identified numerous previously uncharacterized genes that
drive tumor initiation and progression. Using RNAi-based
screening, it is possible to examine hypomorphic pheno-
types in mammalian cells (Berns et al. 2004; Paddison et al.
2004; Ngo et al. 2006; Schlabach et al. 2008; Silva et al.
2008). Recently, pool-based shRNA screening approaches
have been adapted to in vivo applications in transplantable
tumors. shRNA pools were used to screen for tumor
suppressors in mouse models of liver cancer (Zender
et al. 2008), B-cell lymphoma (Bric et al. 2009), and skin
carcinomas (Beronja et al. 2013). Here, we adapted a pool-
based shRNA screening strategy for use in a transplantable
mouse model of B-cell acute lymphoblastic leukemia
(ALL) (Williams et al. 2006). Specifically, we introduced
libraries of retrovirally expressed shRNAs into leukemia
cells and transplanted transduced cells into recipient
animals to screen for genes that impact leukemia cell
growth. In this ALL model, the transplantation of murine
p19Arf/ pre-B cells that express the p185 BCR-ABL fusion
protein (Arf-null, p185+) into immune-competent syngeneic
mice produces an aggressive, disseminated polyclonal B-cell
leukemia within ;2 wk (Williams et al. 2006, 2007).
Importantly, since leukemias are established within wild-
type syngeneic recipient animals, tumor cell growth occurs
in the context of a normal microenvironment and in the
presence of a functional immune system.
Results and Discussion
To determine whether large, unbiased shRNA sets could
be introduced into disseminated leukemias in vivo, we
made use of a genome-scale shRNA library composed of
five pools of shRNAs containing ;10,000 hairpins each.
Leukemia cells were transduced with single pools of
10,000 shRNAs, and infected cells were injected into
recipient mice or, in parallel, placed in culture. Growth in
both contexts allowed us to compare shRNAs that impact
leukemia cell proliferation in vitro and in vivo. In control
experiments, we observed rapid homing of leukemia cells to
the bone marrow and spleen following transplantation
(Supplemental Fig. 1A,B), indicating that leukemia cell
proliferation occurs within these physiological environ-
ments in vivo. Once overt disease developed, leukemia cells
were harvested from the blood of the recipient animals and
from cultured samples, and shRNA representation was
deconvoluted via high-throughput sequencing (Fig. 1A).
Here, we could detect, on average, between 7000 and 8000
unique hairpins in the peripheral leukemia burden derived
from individual mice (Fig. 1B; Supplemental Fig. 2A). To
assess the upper limit of the number of hairpins that can be
detected in the leukemia burden from individual mice, we
combined all five pools of shRNAs and introduced this set of
50,000 hairpins into tumor cells prior to transplantation.
Here, we could identify as many as 30,000 unique shRNAs
in tumors from individual animals at the onset of terminal
disease (Supplemental Fig. 2B,C). Thus, given the high
engraftment efficiency in this model of B-ALL, we can
represent genome-scale shRNA libraries in vivo.
As an initial survey of the data set produced from the
50,000 shRNA pool, the shRNA representation from cul-
tured cells or mice was subjected to hierarchical clustering
based on the enrichment and depletion of shRNAs within
each sample. Here, the in vivo and in vitro samples
clustered as distinct groups (Fig. 1D). In fact, phenotypes
conferred by hairpins in vitro were poorly correlated with
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the phenotypes conferred by the same hairpins in vivo
(Fig. 1C,E; Supplemental Fig. 3A), with limited mutual
information provided when comparing rank-order lists of
enriched and depleted shRNAs in cell culture and mice.
For validation studies, we focused on shRNAs that de-
pleted specifically in the in vivo setting, as these genes
represent a putative new class of leukemia drug targets.
To prioritize shRNAs for validation studies, hairpins that
depleted an average of fourfold in vivo and did not deplete
>25% in vitro were considered candidates for validation.
Using these criteria, we identified;1700 scoring hairpins
that targeted annotated genes, predicted genes, and pre-
dicted proteins (Supplemental Tables 1, 2).
Relative to the in vitro data set, the in vivo data set
showed high mouse-to-mouse variability, (Fig. 1D; Sup-
plemental Fig. 3), suggesting that transplantation and
engraftment as well as the complexity of the in vivo
microenvironment can substantially influence the mea-
sured effect of a relatively neutral shRNA.However, further
inspection of this variation showed that a subset of shRNAs
had lower coefficients of variation (CVs) between mice.
When we examined the CVs between mice for our putative
‘‘scoring shRNAs,’’ the average CVs for these hairpins was
significantly lower than the average CV in vivo (Supple-
mental Fig. 3B–D), and the CVs of candidate depletion hits
were of a size comparable with those produced by shRNAs
that exerted consistent biological effects in previous small-
scale screens. In contrast, randomly selected shRNAs,
validated for neutrality, showed greater variability and
reduced fold change in our data set (Supplemental Fig. 3B).
Thus, the set of low CV shRNAs from our screen is
enriched for validating shRNAs.
Functional categorization of the genes targeted by the
1700 scoring shRNAs (Huang et al. 2009a,b) based on
structural features of proteins encoded by target genes
revealed that these genes were enriched for a number of
common domains (Fig. 2A; Supplemental Table 2B). These
domains included C2H2-type zinc finger protein domains,
which primarily regulate gene expression (Iuchi 2001);
Figure 1. Genome-scale in vivo RNAi screening in a transplantable
model of ALL. (A) A schematic representation of the in vivo screening
strategy. Leukemia cells were transduced with pools of shRNAs and
then grown in culture or injected into recipient mice. shRNA
representation at disease presentation was assessed by high-through-
put sequencing. (B) A scatter plot showing the average number of
hairpins detected across all in vitro and in vivo samples. Each data
point represents an individual sample, and error bars show standard
error of the mean (SEM). (C) Waterfall plots depicting the average log2
fold change of each shRNA in vivo (red) or in vitro (blue) relative to
the input population. shRNAs are arranged in rank ascending order
based on their behavior in vivo (left panel) or in vitro (right panel). (D)
Unsupervised hierarchical clustering of samples based on the enrich-
ment or depletion of shRNAs. Data are shown from an experiment in
which a 50,000 shRNA set was infected into leukemia cells. Only
hairpins represented by 100 or more sequencing reads in the input
sample are shown. (E) A Venn diagram showing the overlap between
the number of shRNAs that depleted an average of fourfold in the in
vivo and in vitro settings.
Figure 2. The tumor microenvironment introduces distinct tumor
growth dependencies relative to growth in culture. (A) A bar graph
showing protein domains and motifs that were enriched in the set of
hairpins that depleted specifically in vivo. (B,C) Scatter plots showing
results from in vivo and in vitro validation assays for shRNAs targeting
genes with Kelch (B) and C2H2 zinc finger (C) domains. Each data point
represents the ratio of the percentage of hairpin-infected GFP-positive
cells harvested from the blood of mice (in vivo samples) or from cells
maintained in culture (in vitro samples) to the percentage of GFP-
positive cells in the input population. P-values were determined using
a Student’s t-test. (D) A schematic representation of the generation of
the validation library and the secondary validation screen. (E) A scatter
plot showing in vitro and in vivo validation assays of individual
shRNAs. P-values were calculated using a Student’s t-test. (F) A scatter
plot showing the effects of Runx1 or Lmo2 suppression in vitro and in
vivo. shLmo2_A and shRunx1_A were the hairpins identified in the
screen. P-values were calculated using a Student’s t-test.
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Kelch and BTB/POZ domains, which are involved in
protein–protein interactions and regulate diverse cellular
processes (Collins et al. 2001); and plant homeodomain
(PHD) fingers, which recognize specific histone modifica-
tions and are part of multimeric complexes that can
activate or repress gene transcription (Musselman and
Kutateladze 2011; Sanchez and Zhou 2011). To assess the
impact of a given hairpin on tumor cell growth, leukemia
cells were partially transduced with single shRNAs coex-
pressing GFP and injected into recipient mice or main-
tained in culture. After a period of in vitro or in vivo
proliferation, the percentage of GFP-positive (shRNA-
expressing) cells was assayed by flow cytometry (Supple-
mental Fig. 4A). In total, out of the 18 shRNAs tested
targeting genes containing Kelch and C2H2 zinc finger
domains, nine depleted as single constructs. Importantly,
eight of these nine shRNAs differentially impacted leuke-
mia cell growth in vivo and in vitro (Fig. 2B,C). The
deleterious effect of shRNA-mediated gene suppression
in vivo was confirmed with second hairpins for these
targets (Supplemental Fig. 4B). While these hairpins were
neutral or, in some instances, provided a growth advantage
in the in vitro context, they depleted during tumor
expansion in mice. Thus, by performing screens in mice,
we identified a number of genes that represent putative in
vivo ‘‘context-specific’’ cancer dependencies that would
not be identified in cell culture-based screens.
To further prioritize shRNAs for validation, we gener-
ated transcriptional data from leukemia cells grown in
vitro and in vivo (Supplemental Fig. 5A). Specifically, we
compared the genes that were transcriptionally up-
regulated in vivo with those that were targeted by hairpins
that depleted specifically in vivo. Notably, only a small
proportion of genes overlapped between the transcrip-
tional and screening data sets (Supplemental Fig. 5B,C;
Supplemental Table 3), a phenomenon that has also been
observed when comparing functional and transcriptional
data in other settings (Yeger-Lotem et al. 2009). To more
extensively probe this overlapping gene set, we built
a high-coverage validation library that contained six in-
dependent shRNAs directed against each of the 133 genes
in this set (Fig. 2D). Only genes that had multiple in-
dependent shRNAs deplete specifically in vivo, but not in
cell culture, in this secondary screen (Supplemental Table
4) were considered candidates for follow-up studies. By this
criteria, this secondary screen validated 77 of the starting
133 genes (58%) as context-specific positive regulators of
tumor growth, and a subset of these was further validated
as single shRNA constructs (Fig. 2E; Supplemental Fig.
5C). Consistent with our previous observations, shRNAs
targeting these 77 genes produced lower CVs than the
nonscoring shRNAs (Supplemental Fig. 3D).
Two of the shRNAs that depleted specifically in the in
vivo setting targeted Lmo2 and Runx1 (Fig. 2F), genes with
established roles in hematopoietic malignancies. LMO2
translocations, resulting in overexpression of the full-
length Lmo2 protein, are found in T-cell malignancies
and have been suggested, at least in part, to promote
tumorigenesis by blocking T-cell development (Curtis
and McCormack 2010; McCormack et al. 2010). Thus
far, LMO2 does not have a well-established role in the
development of B-cell malignancies. Whereas inactivating
mutations and translocations resulting in the truncation of
RUNX1 are observed in myeloid and T-cell malignancies
(Cameron and Neil 2004), full-length RUNX1 is expressed
on translocated alleles in B-cell malignancies (Golub et al.
1995; Romana et al. 1995). Here, bothRunx1 and Lmo2 are
transcriptionally up-regulated in the in vivo setting (Sup-
plemental Fig. 6A), and multiple hairpins targeting these
genes confer a growth disadvantage specifically in vivo
(Fig. 2F; Supplemental Fig. 6B,C). These data indicate that,
in vivo, BCR-ABL-driven B-cell leukemia progression is
dependent on Runx and Lmo2 function.
As a final means of examining our shRNA screening
data using existing biological data sets, we compared
genes targeted by shRNAs that depleted in vivo with
genes contained within amplicons found in human ALL
patients (Kuiper et al. 2007; Mullighan et al. 2008; Zhang
et al. 2012). We mapped the genomic locations of the
human orthologs of genes targeted by scoring shRNAs
and looked for genes that fell within the amplified re-
gions. In validation experiments, a number of shRNAs
targeting genes contained within ALL amplicons con-
ferred minor negative growth effects specifically in vivo
(Fig. 3A). In contrast, hairpins targeting the PHD finger
protein Phf6, located in the XQ26 amplicon, yielded
a more pronounced negative growth effect in validation
Figure 3. Phf6 is a developmentally specified, in vivo-specific
regulator of tumor cell growth. (A) Scatter plot showing the behavior
of single shRNAs in in vitro and in vivo validation assays. All hairpins
target genes found within common amplicons in human ALL.
P-values were calculated using a Student’s t-test. (B) A scatter plot
showing the effect of hairpin-mediated Phf6 suppression on leukemia
cell representation in vitro and in vivo. (C) A graph showing
suppression of the in vivo effect of a Phf6 shRNA in a population of
leukemia cells via expression of a nontargetable Phf6 cDNA. (D)
Scatter plots showing the effect of Phf6 suppression in leukemia cells
harvested from the spleen and bone marrow of tumor-bearing
animals. (E) Peripheral leukemia cell counts 9 d following tumor cell
transplantation. (F) Longitudinal monitoring of the percentage of
vector control or shPhf6-infected leukemia cells in partially trans-
duced tumor cell populations. (G) A scatter plot showing the effect of
Phf6 suppression in distinct Em-myc transplanted B-cell lymphomas.
(H) A graph showing the relative impact of Phf6 suppression in
a transplanted AML. The Phf6 and control shRNAs were induced
with doxycycline at day 14, and the relative percentage of infected
cells over time is shown. (I) Scatter plots showing the impact of Phf6
suppression and overexpression in a transplanted T-cell lymphoma.
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experiments, and selection against Phf6 suppression was
observed in B-ALLs proliferating in vivo but not in vitro
(Fig. 3B). Inactivating mutations in PHF6 are the cause
of B€orjeson-Forssman-Lehman syndrome (BFLS), an X-
linked intellectual disability (XLID) disorder (Lower et al.
2002). Recently, inactivating PHF6 mutations have been
identified in ;25%–30% of human T-cell ALLs (Van
Vlierberghe et al. 2010; Zhang et al. 2012) and in 2%–3%
of acute myeloid leukemias (AMLs) (Supplemental Table 5;
Van Vlierberghe et al. 2011; Patel et al. 2012; Yoo et al.
2012). While the mutational status of PHF6 has been
examined in >100 human B-lineage ALLs (Van Vlierberghe
et al. 2010; Zhang et al. 2012), no PHF6 mutations have
been observed in these tumors (Supplemental Table 5),
suggesting that inactivating mutations do not promote
malignant growth in B-ALL. Strikingly, our data indicate
that suppression of Phf6 actually impairs disease pro-
gression in B-cell ALLs, specifically in the in vivo setting.
The strength of the phenotype conferred by Phf6 sup-
pression correlated with the degree of hairpin-mediated
gene knockdown (Supplemental Fig. 7A), and expression of
a nontargetable Phf6 cDNA suppressed the deleterious
effect of a Phf6 shRNA on tumor cell growth (Fig. 3C).
Phf6 suppression negatively impacted B-cell tumor growth
in all hematopoietic organs tested (Fig. 3D), and we ob-
served a reduction in peripheral leukemia burden in sorted,
transplanted populations of leukemia cells transduced with
an shRNA targeting Phf6 relative to a vector control (Fig.
3E). This effect could be due to either impaired tumor
growth or impaired tumor engraftment. To differentiate
between these possibilities, wemonitored the effect of Phf6
suppression on leukemia growth in vivo at sequential time
points during disease progression and found that the pro-
portion of cells suppressing Phf6 decreased progressively
during disease progression (Fig. 3F). Thus, Phf6 suppression
impairs leukemia cell growth or survival rather than
impairing engraftment following transplantation.
To determine whether Phf6 is required for the growth of
B-cell malignancies driven by other oncogenic lesions, we
also tested the effect of Phf6 suppression in B-cell lym-
phomas derived from Em-Myc mice, which are driven by
expression of high levels of c-Myc. Here, suppression of
Phf6 was also specifically selected against in the in vivo
context in transplanted B-cell lymphomas (Fig. 3G). Addi-
tionally, Phf6 suppression had no effect on nontransformed
pre-B cells (Supplemental Fig. 7B). Together, these data
suggest that Phf6 may be required for the maintenance of
the transformed B-cell malignant state in B-cell diseases
driven by distinct initiating oncogenes. We then tested the
effect of Phf6 suppression in transplantable mouse models
of acute leukemia and lymphoma and found that hairpin-
mediated suppression of Phf6 had a neutral effect in T-cell
lymphomas but promoted significant myeloid tumor cell
(AML) growth in vivo (Fig. 3H,I). Together, these findings
suggest differential requirements for Phf6 gene function in
B-cell, T-cell, and myeloid tumors.
We next tested the effect of cDNA-mediated Phf6 over-
expression in vivo in these transplantable murine tumor
models and found that Phf6 overexpression was potently
selected against in T-cell lymphomas in vivo (Fig. 3I),
whereas it was neutral in B-cell ALLs in vivo (Supplemen-
tal Fig. 7C). These results support a lineage-specific role for
Phf6 in hematopoietic malignancies such that overexpres-
sion of Phf6 impairs tumor cell growth in T-cell malignan-
cies, and suppression of Phf6 hinders disease progression
in B-cell malignancies. These findings are consistent with
human mutational data, where inactivating mutations in
PHF6 are observed in T-cell and myeloid malignancies
but have never been identified in B-cell malignancies.
These findings are similar to our observations describing
a B-ALL dependency on Runx expression and to published
findings showing RUNX inactivation in myeloid or T-cell
malignancies. Such contrasting roles for an established
cancer pathway have been documented for deregulated
Notch signaling (Klinakis et al. 2011). However, unlike
aberrant Notch activity, the effects of Phf6 and Runx
suppression were observed only in vivo, suggesting that
the tumor microenvironment can strongly influence
these ‘‘lineage-specific’’ genetic dependencies.
To gain insight into the molecular function of PHF6 in
leukemia, we performed whole-genome chromatin immu-
noprecipitation (ChIP) coupled with high-throughput se-
quencing (ChIP-seq) using an antibody directed against
Phf6 (Supplemental Fig. 8A,B). Using Jurkat cells, a system
in which chromatin regulators and histone modifications
have been extensively characterized, we found that Phf6
was bound to the promoter regions and within the gene
body ofmany annotated genes (Supplemental Fig. 8C). Phf6
most frequently occupied the promoter region of active
genes, as evidenced by co-occupancy with RNA polymer-
ase II (RNAP2) and the histone modification H3K4me3
(Fig. 4A,B). Interestingly, when we ranked the genes bound
by Phf6 based on ChIP-seq signal (Fig. 4C–F; Supplemental
Table 6), we identified a set of target genes that have
established roles in hematopoietic malignancies. This
gene set included RUNX1, DMNT3A, NOTCH1, and JAG1
(a ligand of Notch). These data suggest that PHF6 may be
involved in a gene regulatory network that influences disease
progression through the modulation of other leukemia-
associated genes. Consistent with this idea, Phf6 sup-
pression resulted in a significant decrease in Runx1 and
Notch levels in B-ALL cells (Supplemental Fig. 9A–C).
The tractable characteristics of this murine pre-B-cell
leukemia permit the introduction of very large, diverse
libraries of shRNAs into individual animals. Specifically,
malignant cells in this model show very high engraftment
efficiency into syngeneic recipient mice. This efficiency
allows for the simultaneous assessment of the impact of
thousands of loss-of-function events in individual tumors.
However, the ultimate relevance of this approach lies in
the number of genes and gene classes that specifically
impact leukemia cell growth in vivo. Here, we identified
a large set of ‘‘context-specific’’ dependencies or acquired
genetic dependency genes that become important for
tumor progression only following transplantation into
the tumor’s native microenvironment. These data also
highlight the relevance of tumor type to cancer therapy.
While many current therapeutic strategies focus on target-
ing cancer-specific alterations, our data suggest that the
effects of targeting the same cancer-relevant pathways
may yield dramatically distinct—and possibly opposite—
outcomes depending on tumor cell identity.
Materials and methods
Cell culture
Bcr-Abl-driven mouse acute B-cell lymphoblastic leukemia cells (Williams
et al. 2006) were cultured in RPMI supplemented with 10% FBS, 4 mM
L-glutamine, and 5 mM b-mercaptoethanol. T-cell lymphomaswere derived
from p53-deficent animals and maintained in IMDM with 10% FBS and
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5 mM b-mercaptoethanol. MLL-AF9-expressing AML cells were maintained
inRPMIwith 10% FBS, 4mML-glutamine, and 500mM b-mercaptoethanol.
RNAi screening and validation assays
The shRNAs were expressed in a mir30 context, and the precise vector
construction has been detailed in the referenced mir30 shRNA study
(Dickins et al. 2005). Detailed screening and validation library informa-
tion is provided in the Supplemental Material. PCR primer sequences are
provided in Supplemental Table 7. Quantitative PCR (qPCR) reactions
were performed on cDNA using the primer sequences in Supplemental
Table 8. Knockdown data not shown in the figures are shown in Supple-
mental Table 9.
Microarray analysis
GFP-expressing leukemia cells (13 106) were injected into nonirradiated
C57BL/6J syngeneic recipient animals or propagated in culture. After
12 d of growth in each condition, 23 106 leukemia cells were sorted from
the peripheral blood of tumor-bearing animals or from cultured samples
and flash-frozen. RNA was extracted from leukemia cells with an
RNeasy kit (Qiagen), and microarrays were performed by the Massachu-
setts Institute of Technology BioMicro Center using Affymetrix Mouse
Genome 430 2.0 arrays.
Western blotting
For Western blots, ALL cells were infected with individual shRNAs
coexpressing GFP to a final infection percentage of 40%–60% and sorted
based on GFP expression, and total protein was isolated from this sorted
cell population. Proteins were detected with the following antibodies:
Phf6 (1:1000 in TBS-T with 5% BSA; Novus Biologicals, NB100-68262),
Runx1 (1:1000 in TBS-T with 5% BSA; Abcam, ab23980), and HSP60
(1:1000 in TBS-T with 5% BSA; Santa Cruz Biotechnology, SC1722).
ImageJ was used to perform protein densitometry.
ChIP-seq
The antibody used for ChIP-seq was specific for PHF6 (Bethyl Laboratories,
A301-451A). All protocols for Illumina sample preparation, sequencing, and
quality controlwere provided by Illumina (http://www.illumina.com). Each
gene in the human genome was classified into active, initiated, bivalent, or
PcG-bound or silent groups based on the presence of co-occupancy of
H3K4me3, H3K79me2, and H3K27me3. Using a hypergeometric test, the
P-value for enrichment of PHF6 binding to the genes in each of these classes
was determined.
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